In the quiet hours before dawn, when the hospital corridors echo only with the hum of machines and the soft tread of nurses’ shoes, patients like Adri Jeffers and Francisca Violeta Sam Colop wage a quieter, more insidious battle — not just against cancer, but against the arithmetic of survival itself. Their stories, scattered across continents from the highlands of Guatemala to the coastal suburbs of Durban, reveal a chilling truth: in the global fight against cancer, access to life-extending treatment often depends less on medical need and more on the ability to navigate a labyrinth of insurance denials, judicial appeals, and financial exhaustion. This is not merely a healthcare crisis; It’s a mirror held up to the fractures in our global solidarity — where the promise of innovation collides with the reality of inequity.
The source material lays bare the human toll of Keytruda’s inaccessibility, but it leaves unexamined the structural forces that allow such disparities to persist. Why, a decade after its FDA approval, does pembrolizumab remain financially out of reach for so many, even in nations with established healthcare systems? To answer that, we must look beyond individual stories to the architecture of pharmaceutical pricing, the evolution of intellectual property law, and the quiet ways in which wealth concentrates power — even in the realm of medicine.
Keytruda’s journey from laboratory breakthrough to global commodity is inseparable from the patent strategy that has shielded it from competition. Merck & Co. Has employed a tactic known as “evergreening,” filing secondary patents on formulations, dosing regimens, and even methods of use to extend its exclusive rights well beyond the original 20-year term. According to a 2024 analysis by the Initiative for Medicines, Access & Knowledge (I-MAK), Merck has filed over 130 patent applications related to Keytruda in the United States alone, with the potential to delay generic entry until as late as 2032. This strategic patent thicket, critics argue, is less about innovation and more about maintaining a monopoly that allows Merck to command prices exceeding $150,000 per year of treatment in the U.S.
“The patent system was designed to reward innovation, not to enable perpetual rent-seeking,”
said Priti Krishtel, co-founder and director of I-MAK, in a 2025 testimony before the U.S. Senate Finance Committee.
“When a single company can block competition for over a decade through incremental patenting, it distorts the market and puts life-saving drugs out of reach — not because they’re costly to make, but because the system allows it.”
This dynamic plays out starkly in middle-income countries like Colombia and Indonesia, where Keytruda’s price varies wildly — from $29,000 to over $130,000 annually — not due to differences in production cost, but because of divergent purchasing power and the absence of robust price-regulation mechanisms. In Colombia, for instance, the drug’s high cost has strained the national health budget, prompting courts to intervene. Yet even when courts rule in favor of patients, enforcement remains patchy. A 2025 study by the Universidad de los Andes found that nearly 40% of court-ordered Keytruda treatments in Colombia faced delays of more than 90 days due to procurement bottlenecks and budgetary reallocations.
In South Africa, the situation is compounded by the structure of private medical aid schemes. Unlike national health systems, these schemes operate on a break-even model, legally prohibited from raising reserves or accessing external capital. High-cost oncology claims — like those for Keytruda — directly impact premiums for all members. “We’re not denying care out of malice,”
explained Dr. Lindiwe Majeke, former executive at the Council for Medical Schemes, in a 2024 interview with Business Day.
“We’re caught in a bind: fund an expensive treatment for one member, and risk destabilizing the entire pool. The system wasn’t built for therapies that cost more than a household’s annual income.”
This tension between individual need and collective sustainability lies at the heart of what scholars call the “judicialization of health care” — a phenomenon particularly pronounced in Latin America, where constitutional courts have increasingly turn into arbiters of medical access. In Guatemala, the Constitutional Court has granted over 95% of amparo petitions for Keytruda since 2022, not because the drug is routinely covered, but because patients have no other recourse. Similarly, in Brazil, federal courts have approved nearly 80% of Keytruda-related lawsuits since 2019, according to data from the National Council of Justice.
Yet these victories are often pyrrhic. Patients win in court, only to face delays in delivery, intermittent shortages, or insurers that reinterpret rulings to limit duration or dosage. In Mexico, although 65% of amparo filings for Keytruda were granted between 2017 and 2026, a follow-up by Quinto Elemento Lab found that fewer than half of those patients received uninterrupted treatment for the full prescribed course.
Even in the United States, where insurance coverage is broader, denial patterns reveal a troubling arbitrariness. A 2025 Kaiser Family Foundation analysis showed that while only 1% of denied Keytruda claims are appealed, over half of those appeals succeed — suggesting that many initial denials are not based on clinical guidelines, but on procedural hurdles or cost-containment instincts. For patients like Lisa Ferguson, the CEO of a healthcare consulting firm in Arizona, the experience was both professionally familiar and personally devastating. “I understand how the system works,” she told ICIJ. “And still, I had to become a full-time advocate just to keep getting the drug that was keeping me alive.”
The human cost of these delays is measurable. A 2024 modeling study published in The Lancet Oncology estimated that in low- and middle-income countries, delays in accessing pembrolizumab beyond six months of diagnosis reduce two-year survival rates by up to 30% for patients with metastatic melanoma or non-small cell lung cancer — the extremely populations for which Keytruda has shown the most dramatic benefit.
Yet amid the frustration, there are flickers of change. In 2023, South Africa’s Competition Commission launched an investigation into potential anti-competitive practices in the oncology drug market, including allegations of excessive pricing and patent evergreening. While no formal charges have been filed, the inquiry has prompted renewed debate about whether essential medicines laws should be expanded to include newer biologics — a shift already underway in countries like Thailand and Malaysia, which have issued compulsory licenses for certain cancer drugs during public health emergencies.
Closer to home, patient advocacy groups are beginning to reframe the narrative. Organizations like Cancer Patients Aid Association (CPAA) in India and Max Foundation in the U.S. Are not only helping individuals navigate insurance denials but also pushing for policy reforms — from tying drug prices to clinical outcomes to accelerating generic entry through patent reform.
As we stand on the precipice of a fresh era in cancer treatment — one defined by personalized immunotherapies and CAR-T therapies that promise even greater efficacy — the question is no longer whether we can innovate, but whether we can ensure that innovation serves everyone. The stories of Francisca, Adri, and Lisa are not outliers; they are early warnings. If we continue to treat access to life-saving drugs as a privilege rather than a right, we risk creating a two-tiered system where survival is determined not by biology, but by geography, income, and tenacity.
So the next time you hear about a breakthrough in oncology, ask not just how it works — but who will get to use it. And then ask yourself: what are we willing to change to make sure the answer is not ‘only the fortunate few’?
